natgillin/translations-raw huggingface dataset:
If aluminium hydroxide is taken concomitantly, allopurinol-containing medicinal products may have an attenuated effect.
Pri sočasni uporabi aluminijevega hidroksida imajo lahko zdravila, ki vsebujejo alopurinol, oslabljen učinek.
Patients taking Duzallo which contains the active substance allopurinol and 6mercaptopurine or azathioprine must reduce their dose to 25 % of the intended dose of 6
Bolniki, ki jemljejo zdravilo Duzallo, ki vsebuje učinkovino alopurinol, in 6-merkaptopurin ali azatioprin, morajo odmerek 6-merkaptopurina ali azatioprina zmanjšati na 25% njim prvotno namenjenega odmerka.
Based on its mechanism of action, lesinurad may not be effective in these patients (see section
Glede na njegov način delovanja, lesinurad pri teh bolnikih morda ni učinkovit (glejte poglavje 5.1).
Hypersensitivity syndrome, Stevens-Johnson-Syndrome (SJS ) and toxic epidermal necrolysis (TEN)
Sindrom preobčutljivosti, Stevens-Johnsonov sindrom (SJS) in toksična epidermalna nekroliza (TEN)
Duzallo and all additional doses of allopurinol should be discontinued immediately at the first appearance of allopurinol-induced skin rash or other signs which may indicate an allergic reaction and additional medical care should be provided as needed.
Zdravljenje z zdravilom Duzallo in vsemi dodatnimi odmerki alopurinola moramo ob prvem pojavu kožnega izpuščaja, povezanega z alopurinolom, ali drugih znakih alergijske reakcije, nemudoma prekiniti in po potrebi uvesti dodatno zdravljenje.
Duzallo has not been studied in patients with severe hepatic impairment; therefore, no dose recommendations can be given for Duzallo.
Študij na bolnikih s hudo okvaro jeter z zdravilom Duzallo niso izvedli, zato priporočil za odmerjanje zdravila Duzallo ni mogoče dati.
Hydroxypropylcellulose Microcrystalline cellulose Lactose monohydrate Crospovidone Magnesium stearate
Jedro tablete hidroksipropilceluloza mikrokristalna celuloza laktoza monohidrat krospovidon magnezijev stearat
Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, medicinal product eruption, alopecia, hair colour changes
Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, angioedem, medikamentozni izpuščaj, alopecija, spremenjena barva las
Duzallo may cause serious kidney problems (see section 4).
Zdravilo Duzallo lahko povzroči resne težave z ledvicami (glejte poglavje 4).
Patients continued their allopurinol dose and were randomised 1:1:1 to receive lesinurad 200 mg, lesinurad 400 mg, or placebo once daily.
Bolniki so še naprej uporabljali svoj odmerek alopurinola in so bili v razmerju 1:1:1 randomizirani na prejemanje 200 mg lesinurada, 400 mg lesinurada ali placeba enkrat na dan.
In clinical trials, lesinurad was administered with food, because the serum uric acid lowering was improved under fed conditions (see section 4.2).
V kliničnih preskušanjih so lesinurad uporabljali s hrano, ker je bilo znižanje sečne kisline v serumu na poln želodec boljše (glejte poglavje 4.2).
6-mercaptopurine and azathioprine
6-merkaptopurin in azatioprin
Salicylates and non-selective uricosuric active substances such as probenecid Salicylates at doses higher than 325 mg per day may decrease the serum uric acid lowering activity of lesinurad and should not be co-administered with Duzallo.
Salicilati in neselektivne urikozurične učinkovine, kot je npr. probenecid Salicilati lahko v odmerkih nad 325 mg na dan oslabijo vpliv lesinurada na znižanje sečne kisline v serumu in se jih ne sme uporabljati skupaj z zdravilom Duzallo.
Hence, medicinal products with known non-selective uricosuric activity such as probenecid or large doses of salicylates may accelerate the excretion of oxypurinol.
Zdravila, ki imajo neselektiven urikozurični učinek, kot ga imata probenecid ali visoki odmerki salicilatov, lahko pospešijo izločanje oksipurinola.
Allopurinol is rapidly absorbed from the gastrointestinal tract and is reported to have a plasma half-life of about one hour.
Alopurinol Alopurinol se hitro absorbira iz prebavil in ima razpolovni čas v plazmi približno 1 uro.
If you forget to take Duzallo
Če ste pozabili vzeti zdravilo Duzallo
Female patients of childbearing age should practice additional methods of contraception and not rely on hormonal contraception alone when taking Duzallo (see sections 4.5 and 4.6).
Ženske v rodni dobi morajo uporabljati dodatne načine kontracepcije in se med jemanjem zdravila Duzallo ne smejo zanašati le na hormonsko kontracepcijo (glejte poglavji 4.5 in 4.6).
Epoxide hydrolase inhibitors (e.g. valproic acid, valpromide) Inhibitors of microsomal Epoxide Hydrolase (mEH) (e.g. valproic acid, valpromide) may interfere with the metabolism of lesinurad.
Zaviralci epoksid-hidrolaze (npr. valprojska kislina, valpromid) Zaviralci mikrosomalne epoksid-hidrolaze (mEH - microsomal Epoxide Hydrolase) (npr. valprojska kislina, valpromid) lahko ovirajo presnovo lesinurada.
Reproductive studies with allopurinol have been performed in rats and rabbits at doses up to twenty times the usual human dose and it was concluded that there was no impaired fertility.
Študije vpliva na razmnoževanje z alopurinolom na podganah in kuncih v odmerkih, ki so do dvajsetkrat višji od običajnih odmerkov pri ljudeh, niso pokazali zmanjšanja plodnosti.
An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both medicinal products.
Povečanje pogostnosti kožnega izpuščaja so opazili pri bolnikih, ki so prejemali ampicilin ali amoksicilin sočasno z alopurinolom, v primerjavi z bolniki, ki niso prejemali obeh zdravil sočasno.
Treatment with lesinurad 200 mg in combination with allopurinol was associated with an increased incidence of serum creatinine elevations, which are related to increased renal uric acid excretion.
Zdravljenje z lesinuradom 200 mg v kombinaciji z alopurinolom je spremljala večja pogostnost zvišanj kreatinina v serumu; ta so povezana z večjim izločanjem sečne kisline v ledvicah.
One study in mice receiving intraperitoneal doses of 50 or 100 mg/kg on days 10 or 13 of gestation resulted in foetal abnormalities, however in a similar study in rats at 120 mg/kg on day 12 of gestation no abnormalities were observed.
V študiji na miših, ki so prejemale alopurinol intraperitonealno v odmerkih 50 ali 100 mg/kg na 10. ali 13. dan brejosti, je prišlo do pojava fetalnih nenormalnosti, vendar v podobni študiji na podganah pri odmerku 120 mg/kg na 12. dan brejosti niso opazili nenormalnosti.
Mean plasma-to-blood ratios of lesinurad AUC and Cmax were approximately 1.8, indicating that it did not penetrate or partition extensively into red blood cells.
Povprečno razmerje AUC in Cmax lesinurada v plazmi in krvi je bilo približno 1,8; to kaže, da ni v veliki meri prodiral ali se porazdelil v eritrocite.
If you stop taking Duzallo
Če ste prenehali jemati zdravilo Duzallo
Oxypurinol is eliminated unchanged in the urine but has a long elimination half-life because it undergoes tubular reabsorption.
Oksipurinol se v seču izloča nespremenjen, vendar ima zaradi tubularne reabsorpcije daljši razpolovni čas izločanja.
Warnings and precautions Talk to your doctor or pharmacist before taking Duzallo if:
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Duzallo se posvetujte z zdravnikom ali farmacevtom:
If the patient is a known carrier of HLA-B*5801, especially in those who are of Han Chinese, Thai or Korean descent, allopurinol should not be started unless there are no other reasonable therapeutic options and the benefits are thought to exceed risks.
Če je znano, da je bolnik nosilec HLA-B*5801 alela, zlasti če je potomec Han Kitajcev, Tajcev ali Korejcev, se zdravljenje z alopurinolom ne bi smelo pričeti, razen v primerih, kadar ni drugih možnosti zdravljenja in so koristi večje od tveganja.
If Duzallo which contains the active substance allopurinol is given concomitantly with chlorpropamide when renal function is poor, there may be an increased risk of prolonged hypoglycaemic activity.
Če uporabljamo zdravilo Duzallo, ki vsebuje učinkovino alopurinol, sočasno s klorpropamidom, lahko ob slabem delovanju ledvic pride do tveganja za podaljšan hipoglikemični učinek.
Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk of lesinurad renal-related adverse reactions may be increased (see sections 4.8 and 5.2).
Bolnike, ki so slabi presnavljalci s CYP2C9, je treba zdraviti previdno, ker imajo lahko večje tveganje za neželene učinke na ledvicah, povezane z lesinuradom (glejte poglavji 4.8 in 5.2).
The kinetics of allopurinol are not likely to be altered other than due to deterioration in renal function (see section 5.2 renal impairment).
Ni verjetno, da bi bila kinetika alopurinola spremenjena, razen zaradi zmanjšanega delovanja ledvic (glejte poglavje 5.2 Okvara ledvic).
It is used to treat gout in adult patients in case allopurinol alone is not controlling your gout.
Uporablja se ga za zdravljenje protina pri odraslih bolnikih, če z alopurinolom samim ne nadzorujete protina.
Do not use this medicine after the expiry date which is stated on the carton or blister foil after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli ali pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
The efficacy of lesinurad 200 mg once daily was studied in 2 multicentre, randomised, double-blind, placebo-controlled clinical studies in 812 adult patients (11% of these patients were elderly, ≥65 years old) with hyperuricaemia and gout in combination with allopurinol (CLEAR1 and CLEAR2).
Učinkovitost 200 mg lesinurada enkrat na dan so proučili v 2 multicentričnih, randomiziranih, dvojno slepih, s placebom kontroliranih kliničnih študijah pri 812 odraslih bolnikih (11% bolnikov je bilo starejših, starih ≥ 65 let) s hiperurikemijo in protinom, ki so ga prejemali v kombinaciji z alopurinolom (CLEAR1 in CLEAR2).
Mild to moderate induction of CYP3A by lesinurad may reduce plasma exposures of co-administered medicinal products that are sensitive substrates of CYP3A.
Blaga do zmerna indukcija CYP3A, ki jo povzroči lesinurad, lahko zmanjša plazemsko izpostavljenost sočasno uporabljenim zdravilom, ki so občutljivi substrati CYP3A.
Tissue concentrations of allopurinol have not been reported in humans, but it is likely that allopurinol and oxypurinol will be present in the highest concentrations in the liver and intestinal mucosa where xanthine oxidase activity is high.
Podatkov o koncentraciji alopurinola v tkivih pri ljudeh ni na voljo, vendar je pričakovati, da se alopurinol in oksipurinol v najvišjih koncentracijah nahajata v jetrih in sluznici prebavil, kjer je visoka aktivnost ksantin-oksidaze.
Other metabolites of allopurinol include allopurinol-riboside and oxypurinol-7-riboside.
Med druge presnovke alopurinola spadata tudi alopurinol-ribozid in oksipurinol-7-ribozid.
Allopurinol is a xanthine-oxidase inhibitor.
Alopurinol je zaviralec ksantin-oksidaze.
Cataract, vision disorders (visual impairment and blurred vision), maculopathy
Očesne bolezni katarakta, spremembe vida (motnja vida in zamegljen vid), makulopatija
Re-challenge should not be undertaken in patients with hypersensitivity syndrome.
Pri bolnikih s preobčutljivostnim sindromom zdravila ne smemo ponovno uvesti.
A causal relationship with lesinurad has not been established.
Vzročna povezanost z lesinuradom ni ugotovljena.
Therefore effective inhibition of xanthine oxidase is maintained over a 24 hour period with a single daily dose of allopurinol.
Učinkovito zaviranje ksantin-oksidaze po enem dnevnem odmerku alopurinola je zato ohranjeno preko 24-urnega obdobja.
Allopurinol is negligibly bound by plasma proteins and therefore variations in protein binding are not thought to significantly alter clearance.
Alopurinol se na plazemske proteine veže v zanemarljivih količinah, zato ni pričakovati, da bi lahko spremembe v vezavi proteinov pomembno vplivale na očistek.
The main metabolite of allopurinol is oxypurinol.
Glavni presnovek alopurinola je oksipurinol.
Screening for HLA-B*5801 should be considered before starting treatment with allopurinol in patient subgroups where the prevalence of this allele is known to be high.
Ugotavljanje HLA-B*5801 alela pred uvedbo zdravljenja z alopurinolom bi bilo smotrno pri podskupinah bolnikov, pri katerih je visoka pojavnost tega alela.
Oxypurinol is a less potent inhibitor of xanthine oxidase than allopurinol, but the plasma half-life of oxypurinol is far more prolonged.
Oksipurinol je šibkejši zaviralec ksantin-oksidaze kot alopurinol, vendar je razpolovni čas oksipurinola v plazmi mnogo daljši.
Do not take Duzallo if: - you are allergic to allopurinol, lesinurad or any of the other ingredients of this medicine (listed in section 6) - you have tumour lysis syndrome - a fast breakdown of cancer cells which can cause high uric acid levels - you have Lesch-Nyhan syndrome - a rare inherited illness that starts in childhood where there is too much uric acid in the blood - your kidneys work very poorly or you have end stage kidney disease (when the kidneys no longer work well enough to meet the body's need) - you have received a kidney transplant - you are on kidney dialysis.
Ne jemljite zdravila Duzallo: - če ste alergični na alopurinol, lesinurad ali katero koli sestavino tega zdravila (navedeno v poglavju 6); - če imate sindrom lize tumorja - hitro razgradnjo rakavih celic, ki lahko povzroči visoko koncentracijo sečne kisline; - če imate Lesch-Nyhanov sindrom - redko podedovano bolezen, ki se začne v otroštvu in jo spremlja zvišana koncentracija sečne kisline v krvi; - če vam ledvice delujejo zelo slabo ali imate končno odpoved ledvic (kadar ledvice več ne delujejo dovolj dobro za potrebe telesa); - če imate presajeno ledvico; - če se zdravite z dializo.
The most frequent renal-related adverse reaction was blood creatinine increased (3.7% with lesinurad 200 mg compared to 2.2% with placebo).
Najpogostejši z ledvicami povezani neželeni učinek je bilo zvišanje kreatinina v serumu (3,7% z lesinuradom 200 mg v primerjavi z 2,2% s placebom).
Duzallo should not be restarted without another explanation for the serum creatinine abnormalities.
Zdravljenja z zdravilom Duzallo ne smemo ponovno uvesti, če za zvišane vrednosti kreatinina v serumu nimamo alternativne razlage.
With administration of allopurinol and cytostatics (e.g. cyclophosphamide, doxorubicin, bleomycin, procarbazine, alkylating agents), blood dyscrasias occur more frequently than when these active substances are administered alone.
Ob uporabi alopurinola in citostatikov (npr. ciklofosfamida, doksorubicin, bleomicina, prokarbazina, alkilirajoče učinkovine), se lahko pojavijo krvne diskrazije pogosteje, kot pri jemanju teh učinkovin samih.
Other organs may also be affected (e.g. liver, lungs, kidneys, pancreas, myocardium, and colon).
Lahko so prizadeti tudi drugi organi (npr. jetra, pljuča, ledvice, trebušna slinavka, miokard in debelo črevo).
The primary efficacy endpoint in both CLEAR1 and CLEAR2 was the proportion of patients achieving a serum uric acid target level of less than 6 mg/dL by Month 6.
Primarni cilj študije učinkovitosti v študijah CLEAR1 in CLEAR2 je bil delež bolnikov, ki so do 6. meseca dosegli ciljno koncentracijo sečne kisline manj kot 6 mg/dl.
If you take more of this medicine than you should, talk to a doctor or go to the nearest hospital immediately.
Če ste vzeli večji odmerek zdravila Duzallo, kot bi smeli Če ste vzeli več zdravila, kot bi smeli, se posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
Post-hoc analyses in a subgroup of patients with high cardiovascular risk at baseline (as defined by transient ischemic attack, angina pectoris, heart failure, myocardial infarction, peripheral vascular disease and/or stroke), showed that the incidence of MACE was 0/39 for placebo and 2/43 for lesinurad 200 mg.
Post hoc analize v podskupini bolnikov z velikim izhodiščnim srčno-žilnim tveganjem (opredeljevali so ga tranzitorna ishemična ataka, angina pektoris, srčno popuščanje, miokardni infarkt, periferna žilna bolezen in/ali možganska kap) so pokazale, da je bila pojavnost MACE med uporabo s placebom 0/39 in z 200 mg lesinurada
Duzallo which contains lesinurad as active substance causes an increase in renal uric acid excretion, which may lead to transient increases in serum creatinine, renal-related adverse reactions and kidney stones (see section 5.1).
Zdravilo Duzallo, ki vsebuje učinkovino lesinurad, poveča izločanje sečne kisline v ledvicah; to lahko povzroči prehodno zvišanje kreatinina v serumu, neželene učinke na ledvicah in ledvične kamne (glejte poglavje 5.1).
Based on pharmacokinetic modelling simulations, patients with moderate renal impairment and reduced CYP2C9 activity (co-administration of a CYP2C9 inhibitor or a CYP2C9 poor metabolizer) are predicted to have an increase in AUC of approximately 200% in comparison to normal renal function and unimpaired CYP2C9 activity.
Na podlagi farmakokinetičnih modelskih simulacij se predvideva, da se pri bolnikih z zmerno okvaro ledvic in zmanjšano aktivnostjo CYP2C9 (zaradi sočasne uporabe zaviralca CYP2C9, ali ker so slabi presnavljalci s CYP2C9) AUC poveča za približno 200% v primerjavi z normalnim delovanjem ledvic in neprizadeto aktivnostjo CYP2C9.
Such patients, taking 300 mg of allopurinol per day will generally have plasma oxypurinol concentrations of 5-10 mg/litre.
Pri takih bolnikih, ki prejemajo 300 mg alopurinola na dan, je običajna plazemska koncentracija oksipurinola 5-10 mg/l.
In patients with moderate renal impairment, the incidence of renal-related adverse reactions was similar across all treatment groups: Lesinurad 200 mg (13.4%) and placebo (12.5%).
Pri bolnikih z zmerno okvaro ledvic je bila pojavnost neželenih učinkov v povezavi z ledvicami v vseh terapevtskih skupinah podobna: lesinurad 200 mg (13,4%) in placebo (12,5%).
Duzallo is not recommended during breastfeeding, as allopurinol passes into the breast milk.
Zdravilu Duzallo se je med dojenjem bolje izogibati, ker se alopurinol izloča v materino mleko.
Patients with a history of kidney stones were permitted entry into the 12-month studies of lesinurad in combination with allopurinol.
Bolniki z anamnezo ledvičnih kamnov so lahko bili vključeni v 12-mesečne študije z lesinuradom v kombinaciji z alopurinolom.
If no HLA-B*5801 genotyping is available for patients with Han Chinese, Thai or Korean descent, the benefits should be thoroughly assessed and considered to outweigh the possible higher risks before starting therapy.
Če genotipizacija HLA-B*5801 alela ni možna pri bolnikih, ki so potomci Han Kitajcev, Tajcev ali Korejcev, je nujno pred pričetkom zdravljenja najprej temeljito proučiti in opredeliti koristi, ki morajo odtehtati večje tveganje.
Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.
Zdravilo Duzallo je indicirano pri odraslih za zdravljenje hiperurikemije pri bolnikih s protinom, ki z ustreznim odmerkom alopurinola samega ne dosežejo ciljne koncentracije sečne kisline v serumu.
Lesinurad is not an in vitro inhibitor of P-glycoprotein, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1, MATE2-K and BSEP.
Lesinurad in vitro ne zavira Pglikoproteina, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1, MATE2-K in BSEP.
In male and female rats, there was no effect on mating or fertility with lesinurad.
Pri podganah moškega in ženskega spola lesinurad ni vplival na parjenje ali plodnost.
For allopurinol, undesirable effects may vary in their incidence depending on the dose received and also when given in combination with other medicinal products.
Za alopurinol je pojavnost neželenih učinkov lahko odvisna od odmerka in tudi od kombinacije z drugimi zdravili.
Allopurinol and its main metabolite oxypurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid.
Alopurinol in njegov glavni presnovek oksipurinol zmanjšujeta raven sečne kisline v plazmi in sečnini tako, da zavirata delovanje encima ksantinoksidaza, ki z oksidacijo pretvori hipoksantin v ksantin in nato ksantin v sečno kislino.
Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter URAT1.
Lesinurad je selektiven zaviralec reabsorpcije sečne kisline, ki zavira prenašalec sečne kisline URAT1.
EU/1/18/1300/003 30 film-coated tablets EU/1/18/1300/004 100 film-coated tablets EU/1/18/1300/006 10 film-coated tablets
EU/1/18/1300/003 30 filmsko obloženih tablet EU/1/18/1300/004 100 filmsko obloženih tablet EU/1/18/1300/006 10 filmsko obloženih tablet
Extensive studies of high oral doses of allopurinol in mice up to 100 mg/kg/day, rats up to 200 mg/kg/day and rabbits up to 150 mg/kg/day during days 8 to 16 of gestation produced no teratogenic effects
Obsežne študije visokih peroralnih odmerkov alopurinola pri miših do 100 mg/kg na dan, pri podganah do 200 mg/kg na dan in kuncih do 150 mg/kg na dan od 8. do 16. dne brejosti niso pokazale teratogenih učinkov.
10 film-coated tablets 30 film-coated tablets 100 film-coated tablets
10 filmsko obloženih tablet 30 filmsko obloženih tablet 100 filmsko obloženih tablet
At the 400 mg dose, when compared with extensive CYP2C9 metabolisers (CYP2C9 *1/*1 [N=41]), increased lesinurad exposures were observed in intermediate CYP2C9 metabolisers (CYP2C9 *1/*3 [N=4], approximately 22% increase in AUC) and in poor CYP2C9 metabolisers (CYP2C9 *3/*3 [N=1], approximately 111% increase in AUC) accompanied with higher lesinurad renal excretion.
Pri odmerku 400 mg, v primerjavi z izrazitimi presnavljalci s CYP2C9 (CYP2C9 *1/*1 [N= 41]) so opažali večjo izpostavljenost lesinuradu pri srednjih presnavljalcih s CYP2C9 (CYP2C9 *1/*3, [N= 4] približno 22% povečanje AUC) in pri slabih presnavljalcih s CYP2C9 (CYP2C9 *3/*3, [N= 1 približno 111% povečanje AUC); to je spremljalo večje izločanje lesinurada skozi ledvice.
EU/1/18/1300/001 30 film-coated tablets EU/1/18/1300/002 100 film-coated tablets EU/1/18/1300/005 10 film-coated tablets
EU/1/18/1300/001 30 filmsko obloženih tablet EU/1/18/1300/002 100 filmsko obloženih tablet EU/1/18/1300/005 10 filmsko obloženih tablet
Duzallo should be used with caution in patients with a CrCL of 30 to less than 45 mL/min (experience with lesinurad in patients with an estimated CrCL (eCrCL) less than 45 mL/min is limited).
Zdravilo Duzallo moramo pri bolnikih z očistkom kreatinina med 30 ml/min in manj kot 45 ml/min uporabljati previdno (izkušnje z lesinuradom pri bolnikih z ocenjenim očistkom kreatinina manj kot 45 ml/min so omejene).
In addition to the inhibition of purine catabolism in some but not all hyperuricaemic patients, de novo purine biosynthesis is depressed via feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase.
Poleg zaviranja katabolizma purinov pride pri nekaterih bolnikih s hiperurikemijo do zaviranja de novo biosinteze purinov preko povratne zanke s hipoksantin-gvanin fosforiboziltransferaze.
Oxypurinol AUC and Cmax was not affected by food.
Hrana ne vpliva na AUC in Cmax oksipurinola.
Approximately 20% of the ingested allopurinol is excreted in the faeces.
Približno 20% zaužitega alopurinola se izloči z blatom.
Particularly in the case of a co-administration with azathioprine or 6mercaptopurine, absorption-reducing or elimination-increasing measures such as haemodialysis are indicated (haemodialysis may be considered in patients with severe renal or hepatic impairment).
Predvsem pri sočasnem jemanju azatioprina in/ali 6-merkaptopurina so pomembni ukrepi, s katerimi zmanjšujemo absorpcijo ali povečujemo izločanje, kot je npr. hemodializa (hemodializo lahko uporabimo pri bolnikih s hudo okvaro delovanja ledvic ali jeter).
By inhibiting URAT1, lesinurad increases uric acid excretion and thereby lowers serum uric acid (sUA).
Z zavrtjem URAT1 lesinurad poveča izločanje sečne kisline in tako zniža sečno kislino v serumu (sUAserum uric acid).